Ruiming Li: Why the COMBO Plus form is a Masterclass in Vascular Repair
Ruiming Li, Strategic Partnerships Development Professional at Curalife, shared a post on LinkedIn:
“The ‘Pro-healing’ disruptor: Why the COMBO Plus form is a Masterclass in Vascular Repair.
Most giants in Cath Lab focus on Mechanical Force.
But OrbusNeich Medical Company Ltd. is winning by focusing on Accelerated Biological Healing.
As your China MedTech Observer, I’m peeling back the layers of the COMBO Plus Dual Therapy Stent.
It’s not just a scaffold; it’s a bio-engineered environment designed to repair the artery from the inside out.
1. Dual therapy:
The ‘Sirolimus plus Antibody’ Synergy
Standard Drug-Eluting Stents (DES) rely on a single defensive move: blocking tissue growth. COMBO Plus plays offense and defense simultaneously:
Defense (Sirolimus Elution):
It uses a Bioabsorbable Polymer on the abluminal side to deliver Sirolimus.
This controls neointimal hyperplasia (restenosis) while ensuring no permanent polymer is left behind to cause long-term inflammation.
Offense (Genous™ Technology):
A world-first circumferential Anti-CD34 Antibody coating.
This acts as a ‘biological magnet,’ capturing Endothelial Progenitor Cells (EPCs) directly from the bloodstream.
The Result:
Instead of waiting months for a ‘dead’ metal surface to be covered, the COMBO Plus proactively recruits the body’s own cells to form a functional endothelial layer.
2. Clinical validation: Short DAPT and Safety
The COMBO platform is backed by a massive clinical footprint, including the Reduce and Harmonee trials.
The reduce Trial: Demonstrated that in ACS (Acute Coronary Syndrome) patients, 3 months of Dual Antiplatelet Therapy (DAPT) was non-inferior to 12 months.
This is a game-changer for high-bleeding-risk patients who need a ‘short-fuse’ recovery.
Superior Healing Profile: Optical Coherence Tomography (OCT) studies consistently show earlier and more uniform strut coverage compared to standard everolimus-eluting stents.
The observer’s stratregic take:
The industry is shifting from ‘Deliverability’ to ‘Vascular Health Restoration’.
The COMBO Plus is a benchmark for Scientific Branding.
By solving the ‘Late-Stent Thrombosis’ anxiety through accelerated endothelialization, OrbusNeich has moved the product from a commodity to a Strategic Safety Investment.
For clinicians handling complex, high-risk cases, this isn’t just about opening a vessel – it’s about ensuring it stays healthy.
The executive question:
Will you investing in ‘Active Biologics’? In a value-based care model, the device that heals fastest wins.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials